CA3117961A1 - Compositions and methods for alpha-1-antitrypsin disorders - Google Patents
Compositions and methods for alpha-1-antitrypsin disorders Download PDFInfo
- Publication number
- CA3117961A1 CA3117961A1 CA3117961A CA3117961A CA3117961A1 CA 3117961 A1 CA3117961 A1 CA 3117961A1 CA 3117961 A CA3117961 A CA 3117961A CA 3117961 A CA3117961 A CA 3117961A CA 3117961 A1 CA3117961 A1 CA 3117961A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- alpha
- antitrypsin
- mutations
- recombinant protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752182P | 2018-10-29 | 2018-10-29 | |
| US62/752,182 | 2018-10-29 | ||
| PCT/US2019/058673 WO2020092448A1 (en) | 2018-10-29 | 2019-10-29 | Compositions and methods for alpha-1-antitrypsin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117961A1 true CA3117961A1 (en) | 2020-05-07 |
Family
ID=68771752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117961A Pending CA3117961A1 (en) | 2018-10-29 | 2019-10-29 | Compositions and methods for alpha-1-antitrypsin disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12497441B2 (https=) |
| EP (1) | EP3873926A1 (https=) |
| JP (2) | JP7731288B2 (https=) |
| KR (1) | KR20210111245A (https=) |
| CN (1) | CN113286816B (https=) |
| AU (1) | AU2019369403B2 (https=) |
| BR (1) | BR112021008200A2 (https=) |
| CA (1) | CA3117961A1 (https=) |
| WO (1) | WO2020092448A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3914261A4 (en) | 2019-01-22 | 2023-06-28 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| KR20210129646A (ko) | 2019-01-22 | 2021-10-28 | 코로 바이오, 인크. | Rna-편집 올리고뉴클레오타이드 및 그의 용도 |
| TW202043469A (zh) | 2019-01-22 | 2020-12-01 | 美商科羅生物公司 | Ｒｎａ編輯之寡核苷酸及其用途 |
| AU2021279027A1 (en) * | 2020-05-28 | 2022-12-08 | Korro Bio, Inc. | Methods and compositions for the ADAR-mediated editing of SERPINA1 |
| EP4240323A1 (en) * | 2020-11-06 | 2023-09-13 | AATEC Medical GmbH | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
| IL303712A (en) * | 2020-12-18 | 2023-08-01 | Cullinan Amber Corp | Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereofלטו |
| CN117942275A (zh) * | 2022-10-31 | 2024-04-30 | 康码（上海）生物科技有限公司 | 一种基于病毒阻断剂的洗手液及其应用 |
| EP4705336A1 (en) * | 2023-05-05 | 2026-03-11 | Paul Thomas King | Novel therapeutic polypeptide |
| EP4730999A1 (en) * | 2023-06-22 | 2026-04-29 | AATEC Medical GmbH | Recombinant aat from yeast to treat transplants |
| EP4480493A1 (en) | 2023-06-22 | 2024-12-25 | AATEC Medical GmbH | A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| GB8909916D0 (en) * | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| CA2386180C (en) | 1999-10-13 | 2010-03-09 | Immunex Corporation | Vectors and methods for recombinant protein expression |
| EP2206720A1 (en) * | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003244515A1 (en) | 2002-02-07 | 2003-09-02 | Novozymes Delta Limited | Albumin-fused anti-angiogenesis peptides |
| CA2534352A1 (en) | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| US20070269442A1 (en) | 2006-05-19 | 2007-11-22 | Robert J. Webber | Chimeric monoclonal antibody recognizing iNOS |
| CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| US20100048680A1 (en) | 2007-01-11 | 2010-02-25 | University Of Florida Research Foundation Inc. | Alpha-1-Antitrypsin Variants and Uses Thereof |
| KR100992526B1 (ko) | 2007-11-21 | 2010-11-05 | 한국과학기술연구원 | 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법 |
| US8341615B2 (en) | 2008-07-11 | 2012-12-25 | International Business Machines Corporation | Single instruction multiple data (SIMD) code generation for parallel loops using versioning and scheduling |
| WO2010123290A2 (ko) | 2009-04-22 | 2010-10-28 | (주)알테오젠 | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 |
| CN110551223A (zh) | 2011-06-28 | 2019-12-10 | 英伊布里克斯有限合伙公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
| US10400029B2 (en) * | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| AU2012275295B2 (en) * | 2011-06-28 | 2016-11-10 | Inhibrx, Lp | WAP domain fusion polypeptides and methods of use thereof |
| AU2013202648B2 (en) | 2012-01-10 | 2016-05-19 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| GB201322091D0 (en) * | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| SG11201703390SA (en) | 2014-10-27 | 2017-05-30 | Inhibrx Lp | Serpin fusion polypeptides and methods of use thereof |
| WO2018183705A1 (en) | 2017-03-29 | 2018-10-04 | Cornell University | Oxidation-resistant aat gene therapy |
| CN110092828B (zh) | 2018-01-31 | 2021-08-24 | 北京大学 | 重组突变体α1-抗胰蛋白酶及其制备和应用 |
-
2019
- 2019-10-29 CA CA3117961A patent/CA3117961A1/en active Pending
- 2019-10-29 CN CN201980084112.0A patent/CN113286816B/zh active Active
- 2019-10-29 WO PCT/US2019/058673 patent/WO2020092448A1/en not_active Ceased
- 2019-10-29 JP JP2021548539A patent/JP7731288B2/ja active Active
- 2019-10-29 KR KR1020217016440A patent/KR20210111245A/ko not_active Ceased
- 2019-10-29 EP EP19813978.4A patent/EP3873926A1/en active Pending
- 2019-10-29 BR BR112021008200A patent/BR112021008200A2/pt unknown
- 2019-10-29 US US17/289,136 patent/US12497441B2/en active Active
- 2019-10-29 AU AU2019369403A patent/AU2019369403B2/en active Active
-
2024
- 2024-06-26 JP JP2024103143A patent/JP2024123234A/ja active Pending
-
2025
- 2025-11-13 US US19/388,528 patent/US20260092099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021008200A2 (pt) | 2021-12-14 |
| CN113286816A (zh) | 2021-08-20 |
| JP7731288B2 (ja) | 2025-08-29 |
| AU2019369403A1 (en) | 2021-05-20 |
| WO2020092448A1 (en) | 2020-05-07 |
| JP2022509517A (ja) | 2022-01-20 |
| KR20210111245A (ko) | 2021-09-10 |
| US20210388059A1 (en) | 2021-12-16 |
| US12497441B2 (en) | 2025-12-16 |
| US20260092099A1 (en) | 2026-04-02 |
| JP2024123234A (ja) | 2024-09-10 |
| CN113286816B (zh) | 2025-04-04 |
| EP3873926A1 (en) | 2021-09-08 |
| AU2019369403B2 (en) | 2025-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260092099A1 (en) | Compositions and methods for alpha-1-antitrypsin disorders | |
| JP6674604B2 (ja) | セルピン融合ポリペプチド及びその使用方法 | |
| KR101629702B1 (ko) | 카잘-형 세린 프로테아제 억제제의 치료학적 적용 | |
| KR100249572B1 (ko) | 면역글로불린 부분을 갖는 융합 단백질 및 이의 제조방법 | |
| Neeper et al. | Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. | |
| RU2722374C1 (ru) | Высокогликозилированный слитый белок на основе фактора свертывания крови человека viii, способ его получения и его применение | |
| AU2019268410B2 (en) | Soluble complement receptor type 1 variants and uses thereof | |
| JP4813603B2 (ja) | 止血活性を有する組換え酵母由来の微小胞およびその使用 | |
| JP2989853B2 (ja) | ポリペプチド、その製造方法、ｄｎａ塩基配列及び形質転換細胞宿主 | |
| JPH07503369A (ja) | 血小板及び／又は内皮下層へのｖＷＦの結合の拮抗剤である抗血栓性ポリペプチド | |
| JP2014528913A (ja) | Ｗａｐドメイン融合ポリペプチド及びその使用方法 | |
| JP2020504084A (ja) | 赤血球標的化第ｖｉｉｉ因子およびその使用方法 | |
| WO2018032639A1 (zh) | 活化的人凝血因子vii融合蛋白及其制备方法与用途 | |
| JPH05213998A (ja) | 新規なポリペプチド及びこれを有効成分とする 医薬組成物 | |
| RU2846432C2 (ru) | Слитые серпиновые полипептиды и способы их применения | |
| HK40116728A (en) | Soluble complement receptor type 1 variants and uses thereof | |
| AU2008214916B2 (en) | Therapeutic application of Kazal-type serine protease inhibitors | |
| HK40050759A (en) | Soluble complement receptor type 1 variants and uses thereof | |
| HK40050759B (en) | Soluble complement receptor type 1 variants and uses thereof | |
| IE84574B1 (en) | Fusion proteins with parts of immunoglobulins, their production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241008 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241008 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241008 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241017 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241017 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |